Paolo Tarantino/X
Apr 28, 2025, 07:24
Paolo Tarantino: Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC – by Rodrigo Sánchez-Bayona. The ERBB2 score identified 36% of patients having poor outcomes with chemo-HP (many of which having HER2 IHC ≤2+). Data with T-DXd/P in these patients highly awaited.”
Authors: Rodrigo Sánchez-Bayona et al.
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 06:14
Apr 28, 2025, 04:27
Apr 28, 2025, 03:56
Apr 28, 2025, 03:45
Apr 27, 2025, 20:24
Apr 27, 2025, 20:04
Apr 27, 2025, 19:48